



This is a repository copy of *Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/111326/>

Version: Supplemental Material

Article:

Diaz, J., Sternberg, C.N., Mehmud, F. et al. (4 more authors) (2016) Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. *Oncology*, 90 (3). pp. 119-126. ISSN 0030-2414

<https://doi.org/10.1159/000443647>

This is the peer-reviewed but unedited manuscript version of the following article: Diaz J, Sternberg C, N, Mehmud F, Delea T, E, Latimer N, Pandite L, Motzer R, J, Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. *Oncology* 2016;90:119-126. The final, published version is available at <http://www.karger.com/?doi=10.1159/000443647>

Reuse


Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



Patients at Risk

Pazopanib	155	110	74	48	7
Placebo	78	47	40	32	5